Re: Novavax SARS-CoV-2 vaccine candidate shows promise in animal models
Let's see how the novavax vaccine did in baboons vs the Pfizer vaccine in humans. The Pfier vaccine shows in humans:
At day 28 (7 days after dose 2), all subjects who received 10 g or 30g of BNT162b1 had significantly elevated RBD-binding IgG antibodies with geometric mean concentrations (GMCs) of 4,813 units/ml and 27,872 units/ml which are 8- and 46.3-times, respectively, the GMC of 602 units/ml in a panel of 38 sera of convalescent patients who had contracted SARS-CoV-2
At day 28 (7 days after dose 2), all subjects who received 10 g or 30 g of BNT162b1 had SARS-CoV-2 neutralizing antibodies with geometric mean titers (GMTs) of 168 and 267, which are 1.8- and 2.8-times, respectively, the GMT of the convalescent serum panel
For the Novavax baboons: When compared with the antibody levels in recovered COVID-19 patients, the titers were seven times higher in the baboons than in the latter, along with 8-fold higher receptor binding and blocking antibodies.
So it appears Novavax's vaccine generates 7x neutralizing antibodies in baboons compared to Pfizer's 1.8x - 2.8x in humans. Am I reading this correctly?